EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparison of the Novel Thrombolytic Constitutively Active ADAMTS13 With Clinical Thrombolytics in a Murine Stroke Model

Lucy Roberts iD, Graham Coutts iD, Ben R Dickie iD, Craig J Smith iD, Kieron South iD, Stuart M Allan iD

Stroke · 2025

DOI: 10.1161/strokeaha.125.050848 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Stroke, 2025. Verfasst von Lucy Roberts und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neuroscience, School of Biological Sciences (L.R., G.C., K.S., S.M.A.), Faculty of Biology, Medicine and Health, Manchester Academic Heal…. Hauptthemen laut MEDLINE: ADAMTS13 Protein, Fibrinolytic Agents, Tissue Plasminogen Activator, Stroke. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: r-tPA (recombinant tissue-type plasminogen activator) and its variant, TNK (tenecteplase), are the currently approved thrombolytic drugs for the treatment of acute ischemic stroke, but they are ineffective in a proportion of patients due to r-tPA resistance of platelet-rich thrombi. A novel thrombolytic, caADAMTS13 (constitutively active a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) has been shown to improve experimental stroke outcomes where platelet-rich thrombi are present but have not been directly compared with r-tPA or TNK. METHODS: We conducted a direct comparison of caADAMTS13 versus r-tPA versus TNK versus vehicle control in the ferric chloride–mediated distal middle cerebral artery occlusion model in mice, which features platelet and VWF (von Willebrand Factor)–rich thrombi that reproduce r-tPA-resistant occlusion. Treatments were administered intravenously 1 hour after ferric chloride application by bolus injection or bolus followed by infusion, as translationally applicable. Laser speckle contrast imaging measured early reperfusion over the hour following treatment, and magnetic resonance imaging measured cerebral blood flow and lesion volume at 24 hours. RESULTS: Reperfusion 1 hour after treatment was greatest in caADAMTS13-treated animals. Later cerebral blood flow, 24 hours post-treatment, within the stroke-affected hypoperfused area was higher in caADAMTS13 and r-tPA but not TNK-treated mice. Functionally, this led to the absence of an initial behavioral deficit in caADAMTS13-treated mice, alongside a smaller lesion volume at 24 hours and reduced extent of bleeding. CONCLUSIONS: These findings demonstrate an overall suggestion that caADAMTS13 has improved thrombolytic efficacy, compared with current stroke treatments, against platelet-rich thrombi, for which there is currently an unmet clinical need.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ADAMTS13 ProteinFibrinolytic AgentsTissue Plasminogen ActivatorStrokeThrombolytic TherapyInfarction, Middle Cerebral ArteryAnimalsMiceDisease Models, AnimalMaleMice, Inbred C57BLChloridesCerebrovascular CirculationFerric Compounds

Stichwörter der Autor:innen

cardiovascular diseasescerebral hemorrhagefibrinolytic agentsischemic stroketherapeuticsthrombolytic therapy

Substanzen

ADAMTS13 ProteinFibrinolytic AgentsTissue Plasminogen ActivatorADAMTS13 protein, mouseferric chlorideChloridesFerric Compounds

Autor:innen und Institutionen

  • Division of Neuroscience, School of Biological Sciences (L.R., G.C., K.S., S.M.A.), Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, United Kingdom.
  • Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, Northern Care Alliance NHS Foundation Trust, The University of Manchester, United Kingdom (L.R., G.C., B.R.D., C.J.S., K.S., S.M.A.).
  • Division of Informatics, Imaging and Data Sciences, School of Health Sciences (B.R.D.), Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, United Kingdom.
  • Division of Cardiovascular Sciences, School of Medical Sciences (C.J.S.), Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, The University of Manchester, United Kingdom.
  • Manchester Centre for Clinical Neurosciences, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, United Kingdom (C.J.S.).

ORCID-Profile: Lucy Roberts, Graham Coutts, Ben R Dickie, Craig J Smith, Kieron South, Stuart M Allan

Zitieren

APA

Roberts, L., Coutts, G., Dickie, B. R., Smith, C. J., South, K., & Allan, S. M. (2025). Comparison of the Novel Thrombolytic Constitutively Active ADAMTS13 With Clinical Thrombolytics in a Murine Stroke Model. Stroke. https://doi.org/10.1161/strokeaha.125.050848

Vancouver

Roberts L, Coutts G, Dickie BR, Smith CJ, South K, Allan SM. Comparison of the Novel Thrombolytic Constitutively Active ADAMTS13 With Clinical Thrombolytics in a Murine Stroke Model. Stroke. 2025. doi:10.1161/strokeaha.125.050848

BibTeX
@article{Roberts2025,
  author = {Roberts, Lucy and Coutts, Graham and Dickie, Ben R and Smith, Craig J and South, Kieron and Allan, Stuart M},
  title = {Comparison of the Novel Thrombolytic Constitutively Active ADAMTS13 With Clinical Thrombolytics in a Murine Stroke Model},
  journal = {Stroke},
  year = {2025},
  doi = {10.1161/strokeaha.125.050848}
}
Kostenlos starten →